Exclusive Summary

• Originator patents have expired globally with zero IP risks, making it optimal for rapid market entry and direct substitution by regional distributors.
• Driven by the massive burden of cardiovascular disease (17.9M+ annual deaths globally) and surging PCI procedure volumes, the rigid market demand for this acute antiplatelet agent continues to soar.
• Strongly recommended by major global cardiology guidelines (ESC/AHA), it maintains an irreplaceable clinical position in treating ACS and as a critical adjunct during complex PCI procedures.
• Leveraging China's integrated API-to-finished-dose supply chain, it offers disruptive pricing against the originator and competing generics, securing lucrative profit margins for overseas distributors.